HER3-DXd (Clinical Trial)
Funding Details
Awarder
RSS - www.prnewswire.com
Date Award
May 31, 2025
Vertical
Pharmaceuticals
Funding URL
View Funding Page
Company Info
Traction
The phase II TUXEDO-3 study has shown promising results, indicating potential for significant impact in the oncology market.
Market
Oncology
Location
USA
Company Description

HER3-DXd is a novel therapeutic agent showing promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options.

Links
Website
Back to HomeBack to Pharmaceuticals DealsView Funding Announcement